Plain-English translation of NCT07619157 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new medication called to see if it is safe and well-tolerated in healthy people and in patients with chronic kidney disease and type 2 diabetes. The study will give participants either the medication or a placebo (a dummy pill) in single or multiple doses and monitor how their bodies respond. Researchers want to understand how the medication works in the body and whether it could help protect kidney function in people with diabetes.
Many people with type 2 diabetes develop kidney disease over time, which can lead to serious complications. This medication may help protect the kidneys in people with diabetes, but researchers first need to confirm it is safe and understand how it behaves in the body before larger studies can test whether it actually helps.
You likely qualify if…
You likely don't qualify if…
Participants will visit the study center multiple times to receive either the medication or a placebo pill by mouth. Some participants will receive a single dose, while others will receive multiple doses over time. During visits, the research team will collect blood and urine samples, monitor vital signs, and ask about any side effects or health changes. The study is designed to gather detailed safety information and understand how the medication moves through and affects the body.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
Japan
Phase
Safety & dosing
Sponsor
Ono Pharmaceutical Co., Ltd.
Enrollment target
~120 participants
Started
June 2026
Primary completion
November 2027
Age range
18 Years – 64 Years
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ono Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.